最新ニュース Cytokinetics (NASDAQ:CYTK) 株価情報

Cytokinetics

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics, Incorporated - Common Stock

Cytokinetics Inc

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>), noting the company&#8217;s catalyst rich one to two years.
The M&amp;A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36413624/cytokinetics-drug-potential-analyst-suggests-key-role-of-established-pharma-for-pot" target="_blank" rel="noreferrer noopener">trial data of&nbsp;aficamten</a> in December 2023. However, last year,&nbsp;Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) decided to step back from pursuing <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36616494/cytokinetics-heart-drug-is-a-multi-billion-dollar-opportunity-by-2032-despite-novar" target="_blank" rel="noreferrer noopener">the&nbsp;Cytokinetics deal</a>.
Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) also all popped up as potential suitors, though the stock faded from there as a deal never materialized.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/09/40778617/cytokinetics-sets-stage-for-mid-stage-study-for-heart-failure-drug-after-encouraging-data-from-ph" target="_blank" rel="noreferrer noopener">Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study</a>
Cytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) deal and no <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38992589/heart-disease-focused-cytokinetics-operations-are-on-track-despite-acquisition-unce" target="_blank" rel="noreferrer noopener">mergers or acquisitions</a>.
Investors poorly received the structure of the Royalty Pharma deal at the time, and it continues to be a concern for many even today.
Stifel has initiated coverage with a Buy rating and a <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $80</a>. However, the outlook appears promising, with its valuation adjusted and several catalysts expected over the next 12+ months.
Stifel analyst James Condulis writes Cytokinetics&#8217; aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy (oHCM) market.
As the rollout of Bristol Myers Squibb Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Camzyos mavacamten continues, some concerns remain about its potential in treating obstructive hypertrophic cardiomyopathy (oHCM).
While the initial launch is not seen as a negative sign for mavacamten&#8217;s potential, its Risk Evaluation and Mitigation Strategy (REMS) is a barrier to fully unlocking the market.
Cytokinetics appears well-positioned to capitalize on Bristol Myers&#8217; groundwork with its second-to-market drug, aficamten, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms (Q6M echos) as a standard.
Under conservative assumptions, aficamten could drive the U.S. oHCM market to approximately $3 billion.
Looking ahead to 2025 and 2026, Phase 3 nHCM data and early findings for HFpEF could present new opportunities. Although mergers and acquisitions are not a key focus, potential strategic interest could bring unexpected benefits.
Price Action: CYTK stock is up 3.45% at $47.40 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43131221/halliburton-faces-mixed-q4-with-north-american-weakness-but-global-gains-and-cash-flow-bolster-optimism" target="_blank" rel="noreferrer noopener">Halliburton Faces Mixed Q4 With North American Weakness, But Global Gains And Cash Flow Bolster Optimism</a></li>
</ul>

Analyst Color

Biotech

News

Health Care

Price Target

Initiation

Analyst Ratings

Movers

Trading Ideas

General

AMGN

CYTK

RPRX

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Canaccord Genuity analyst Caitlin Burrows initiated coverage on Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Buy rating and announced a price target of $24. Orthofix Medical shares closed at $18.36 on Tuesday. <a href="https://www.benzinga.com/quote/OFIX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst James Kirby initiated coverage on Sun Country Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCY#NASDAQ">SNCY</a>) with an Overweight rating and announced a price target of $23. Sun Country Airlines shares closed at $16.63 on Tuesday. <a href="https://www.benzinga.com/quote/SNCY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Lizzie Dove initiated coverage on Viking Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Neutral rating and announced a price target of $49. Viking Holdings shares closed at $48.49 on Tuesday. <a href="https://www.benzinga.com/quote/VIK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst James Condulis initiated coverage on Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy rating and announced a price target of $80. Cytokinetics shares closed at $45.82 on Tuesday. <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Gil Blum initiated coverage on Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) with a Buy rating and announced a price target of $9. Absci shares closed at $3.22 on Tuesday. <a href="https://www.benzinga.com/quote/ABSI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CYTK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22070309/image-149-1024x592.png" alt="" class="wp-image-744560" style="width:540px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22070309/image-149-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22070309/image-149-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22070309/image-149-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22070309/image-149.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43119868/netflix-procter-gamble-and-3-stocks-to-watch-heading-into-wednesday">Netflix, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Wednesday</a></li>
</ul>

Pre-Market Outlook

Markets

ABSI

OFIX

SNCY

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Stifel analyst James Condulis initiates coverage on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy rating and announces Price Target of $80.

Stifel Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $80

JMP Securities analyst Jason Butler reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Market Outperform and maintains $78 price target.

JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $78 Price Target

<ul>
<li>PDUFA Target Action Date for Aficamten Set for&nbsp;September 26, 2025.</li>
<li>Commercial Launch Preparations Underway for First Potential Approval.</li>
<li>Five-Year Aspirations Outline Corporate Strategies</li>
</ul>

Cytokinetics Outlined Its Aspirational Vision 2030, Five-year Strategic Objectives

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) from Buy to Buy.

HC Wainwright & Co. Reiterates Buy on Cytokineticsto Buy

Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP).

Government

Regulations

Cytokinetics' Heart Drug Aficamten Gains EMA Validation for Review

WIIM

Cytokinetics shares are trading higher after the company announced that Sanofi will acquire exclusive rights from Corxel Pharmaceuticals to develop and commercialize aficamten in Greater China for the treatment of hypertrophic cardiomyopathy.

In 2020, CORXEL (formerly Ji Xing) acquired the rights to develop and commercialize aficamten in Greater China (including the Chinese mainland, Hong Kong SAR and Macau SAR, and Taiwan) from Cytokinetics in accordance with Cytokinetics' global registration programs. Aficamten received Breakthrough Therapy Designation for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from The Center for Drug Evaluation of the China National Medical Products Administration which recently accepted the New Drug Application for aficamten tablets for&nbsp;the treatment of oHCM for Priority Review.
Sanofi will now acquire CORXEL's rights relating to aficamten in Greater China for an undisclosed amount. Cytokinetics&nbsp;remains eligible to receive up to $150 million in development and commercial milestone payments from Sanofi as well as royalties in the low-to-high teens on future sales of aficamten in Greater China. Cytokinetics is now also eligible to receive additional undisclosed payments in connection with the execution of the agreement between Sanofi and CORXEL.

Cytokinetics Announces Sanofi's Acquisition Of Aficamten Rights For HCM Treatment In Greater China

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Outperform and raises the price target from $80 to $82.

RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $82

Cytokinetics Launches Phase 3 COMET-HF Trial For Omecamtiv Mecarbil In Severe Heart Failure Patients

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $72 price target.

Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target

The FDA Has Accepted Cytokinetics' New Drug Application For Aficamten For Obstructive Hypertrophic Cardiomyopathy, PDUFA Target Action Date Set for September 26, 2025

Cytokinetics (CYTK) CEO Robert Blum is "very clear" that the company, which is on track for U.S. approval in September for aficamten to treat a ser...

Cytokinetics CEO not looking to be bought, but would listen, STAT says

Morgan Stanley analyst Jeffrey Hung maintained a Hold rating on Cytokinetics (CYTK – Research Report) today and set a price target of $70.00. Jeffr...

Cautious Hold on Cytokinetics Amid Regulatory Uncertainties and Distant Milestones

JMP Securities analyst Jason Butler reiterated a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00. Jason ...

Cytokinetics' Promising Future: Aficamten Approval and Robust Pipeline Drive Growth Prospects

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Cytokinetics (CYTK – Research Report) today. The company's shares closed y...

Truist Financial Reaffirms Their Buy Rating on Cytokinetics (CYTK)

Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-...

Cytokinetics announces start of AMBER-HFpEF, Phase 2 trial of CK-586

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CYTK stock, giving a Buy rating on January 14. Joseph Pantginis's r...

Cytokinetics' Innovative CK-586 Advances Bolster Buy Rating Amid HFpEF Promise

Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics "is an out-of-favor stock" following the "cont...

Cytokinetics initiated with a Buy at Stifel

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Netflix upgraded, Reddit downgraded: Wall Street's top analyst calls

Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup

Cytokinetics started at buy by Stifel, aficamten highlighted

CELH

DAKT

EWTX

NFLX

RDDT

Press Releases

Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Cytokinetics to Participate in December Investor Conferences

Cytokinetics Announces Start of COMET-HF,  a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

Comments

Cytokinetics

ニュース

最新ニュース Cytokinetics (NASDAQ:CYTK) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル